Treatment patterns, outcomes and health care resource utilisation in patients with metastatic renal cell carcinoma (RCC)

Treatment patterns, outcomes and health care resource utilisation in patients with metastatic renal cell carcinoma (RCC) - POEM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043018

Enrollment

1000

Registered

2021-01-18

Start date

2021-01-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a.Patients with mRCC diagnosis histologically or clinically confirmed prior to starting systemic anti-cancer therapy such as 1L line, pembrolizumab/axitinib, avelumab/axitinib, nivolumab/ipilimumab, sunitinib, pazopanib, cabozantinib, sorafenib, IFN, low dose IL-2, temsirolimus. b.Patients who start 1L systemic anti-cancer treatment for mRCC at a participating centre between Q4 2020 and Q4 2023. In addition to patients presenting with de novo metastatic disease, this will also include patients who were diagnosed at an earlier stage of disease and who will start 1L treatment for mRCC after recurrence or progression. c.Patient who have data on International Metastatic RCC Database Consortium (IMDC) risk classification. d.Patient with at least 20 years of age at the time of diagnosis of mRCC. e.Patient treated with neoadjuvant or adjuvant treatment in the non-metastatic setting are allowed in the study unless they received the treatment as clinical trials/stu

Exclusion criteria

Exclusion criteria: a.Patient who have any active cancer or undergoing treatment for cancer other than mRCC b.Patient received/about to receive 1L systemic anti-cancer treatment as a clinical trial participant. c.Patient's last adjuvant treatment for RCC was less than 4 weeks (i.e. 28 days) d.Investigator determined the patient to be ineligible due to incomplete medical records at the time of enrolment. Incomplete medical records might be observed for patients who recently transferred to the site without diagnosis or treatment records, or for patients who attended the site only for consultation or second opinion. e.Patients those can be treated with curative intent through either surgical resection and/or percutaneous local therapy will be excluded. a.Patients with transitional cell carcinoma of the renal pelvis or ureter

Design outcomes

Primary

Measure	Time frame
Real-World Treatment Patterns	—

Countries

Japan

Contacts

Public ContactMasaharu Okamoto

IQVIA Services Japan K.K. Real World Evidence Services, Real World & Analytics Soulutions

masaharu.okamoto@iqvia.com080-4733-9431

Outcome results